Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures

NEWPORT BEACH, Calif. & SEATTLE--(BUSINESS WIRE)--Myosana Therapeutics, Inc., a new biotech company developing novel platform technology for non-viral gene delivery, raised up to $1M in seed financing from CureDuchenne Ventures. Myosana will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD). Myosana Therapeutics was founded in 2018 by University of Washington School of Medicine faculty

Click to view original post